KETOROLAC HIGH GASTRIC ULCER INCIDENCE SHOULD BE WEIGHED IN SHORT-TERM THERAPY
KETOROLAC HIGH GASTRIC ULCER INCIDENCE SHOULD BE WEIGHED IN SHORT-TERM THERAPY, according to the authors of a study to be published in the January issue of Epidemiology. The study, "Gastroduodenal toxicity of different nonsteroidal anti- inflammatory drugs," by researchers Giuseppe Traversa, Instituto Superiore di Sanua, Rome, Alexander Walker, Harvard School of Public Health, et al., concluded that the "use of ketorolac appears to carry a greater gastrotoxicity than other NSAIDs." Syntex markets ketorolac in oral and intramuscular forms as Toradol.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth